Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.
Karacin C, Eren T, Zeynelgil E, Imamoglu GI, Altinbas M, Karadag I, Basal FB, Bilgetekin I, Sutcuoglu O, Yazici O, Ozdemir N, Ozet A, Yildiz Y, Esen SA, Ucar G, Uncu D, Dinc B, Aykan MB, Erturk İ, Karadurmus N, Civelek B, Çelik İ, Ergun Y, Dogan M, Oksuzoglu OB. Karacin C, et al. Among authors: aykan mb. Future Oncol. 2021 Nov;17(33):4447-4456. doi: 10.2217/fon-2021-0597. Epub 2021 Aug 3. Future Oncol. 2021. PMID: 34342517 Free PMC article.
Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation.
Erturk I, Karadurmus N, Kızıloz H, Acar R, Yildiz B, Aykan MB, Esen R, Buyukturan G, Urun Y, Erdem G, Arpacı F. Erturk I, et al. Among authors: aykan mb. J Oncol Pharm Pract. 2021 Oct;27(7):1657-1664. doi: 10.1177/1078155220964540. Epub 2020 Oct 13. J Oncol Pharm Pract. 2021. PMID: 33050802
Clinical presentation and course of the novel coronavirus disease 2019 in patients with various types of cancer: A retrospective case-control analysis of an experienced cancer center in Turkey.
Acar R, Yilmaz G, Savasci U, Aykan MB, Kiziloz H, Cuce F, Kadioglu E, Filiz M, Fidan G, Eksert S, Taskin G, Dogan D, Arslan Y, Tasci C, Kayahan N, Dogan T, Basgoz BB, Sertoglu E, Erturk I, Keskin GSY, Okcelik S, Yildiz B, Karadurmus N. Acar R, et al. Among authors: aykan mb. J Cancer Res Ther. 2021 Apr-Jun;17(2):556-564. doi: 10.4103/jcrt.JCRT_715_20. J Cancer Res Ther. 2021. PMID: 34121708 Free article.
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Aktürk Esen S, Ergun Y, Erol C, Arikan R, Er MM, Atci MM, Topçu A, Uçar G, Akagündüz B, Aykan MB, Özen M, Baytemur NK, Özçelik M, Şahin E, Güven D, Menekşe S, Ak N, Teker F, Kut E, Şakalar T, Alan Ö, Kaçan T, Turhal NS, Kiliçkap S, Türker S, Şendur MAN, Köstek O, Karaağaç M, Sakin A, Türk HM, Çağlayan D, Cihan Ş, Açikgöz Y, Uncu D. Aktürk Esen S, et al. Among authors: aykan mb. Bosn J Basic Med Sci. 2022 Sep 16;22(5):818-825. doi: 10.17305/bjbms.2021.7069. Bosn J Basic Med Sci. 2022. PMID: 35460397 Free PMC article.
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.
Özdemir Ö, Zengel B, Yildiz Y, Uluç BO, Cabuk D, Ozden E, Salim DK, Paydas S, Demir A, Diker O, Pilanci KN, Sönmez ÖU, Vatansever S, Dogan I, Gulmez A, Cakar B, Gursoy P, Yildirim ME, Ayhan M, Karadurmus N, Aykan MB, Cevik GT, Sakalar T, Hacibekiroglu I, Gülbagci BB, Dincer M, Garbioglu DB, Kemal Y, Nayir E, Taskaynatan H, Yilmaz M, Avci O, Sari M, Coban E, Atci MM, Esen SA, Telli TA, Karatas F, Inal A, Demir H, Kalkan NO, Yilmaz C, Tasli F, Alacacioglu A. Özdemir Ö, et al. Among authors: aykan mb. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310. Epub 2022 Jun 20. Anticancer Drugs. 2022. PMID: 35703239
Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.
Goktas Aydin S, Cakan Demirel B, Bilici A, Topcu A, Aykan MB, Kahraman S, Akbıyık I, Atci MM, Olmez OF, Yaren A, Sendur MAN, Geredeli C, Seker M, Urun Y, Karadurmus N, Aydin A. Goktas Aydin S, et al. Among authors: aykan mb. Curr Med Res Opin. 2022 Oct;38(10):1751-1758. doi: 10.1080/03007995.2022.2108619. Epub 2022 Aug 16. Curr Med Res Opin. 2022. PMID: 35916475
32 results